ERBB2 and neoplasm: Finally, we reasoned that if preexisting and comingled cell populations were to be treated using an approach targeting both the AR activity–high and HER2 activity–high tumor cells, the exposure paradigm would need to be additive rather than synergistic, because the target cells are separate populations, as suggested by our organoid experiments (see Supplemental Figure 7).